Prenatal Formulation Controls

Prenatal formulation controls are the discipline of formulating, manufacturing and labelling supplements for the preconception, pregnancy and lactation window under the tightest consumer-supplement risk envelope. Folate is the established case — 400-600 µg/day folic acid or 5-MTHF supports neural tube defect risk reduction with the 1000 µg/day synthetic folate UL. Iron at 27 mg/day prenatal RDA with tolerability-driven form selection (ferrous sulphate, bisglycinate, carbonyl iron, polysaccharide-iron complex). Iodine at 150-220 µg/day with 1100 µg/day UL, with 150 µg potassium iodide per dose the American Thyroid Association recommendation for prenatals. Vitamin A teratogenicity above approximately 10,000 IU/day preformed retinol drives the 3000 µg RAE/day pregnancy UL — beta-carotene is the non-teratogenic provitamin A form. Other UL-sensitive nutrients (vitamin D, B6, zinc, selenium, copper, manganese) require formulation against pregnancy-specific UL. A contraindicated and cautioned botanical register (comfrey, pennyroyal, blue cohosh, dong quai, kava, ephedra absolute; ginger, red raspberry leaf, echinacea, garlic high-dose, ginkgo, ginseng cautioned) gates BOM formulation for prenatal SKUs. Heavy metal ceilings in prenatal SKUs are tighter than general adult — California Prop 65 lead MADL 0.5 µg/day and cadmium MADL 4.1 µg/day drive de facto prenatal ceilings well below USP <232> 5 µg/day general lead limit, with mass-retailer and pharmacy specifications sometimes below 0.1 µg/serving requiring per-lot ICP-MS testing against the prenatal limit. DHA from algal or fish oil source qualified for low environmental contaminant load per GOED Voluntary Monograph with oxidation control across shelf life. Pharmacovigilance treats every prenatal/lactation AER as elevated-risk by default with immediate Serious AER triage and accelerated investigation.